Dapagliflozin | sciencenewsnet.in

Breaking News

Technological Breakthrough in Carbon Nanotube Applications for Battery Dry Process

Lack of control at work identified as cause for physician burnout and attrition

Expanding HPV vaccination to all adults aged 27-45 years unlikely to be cost-effective or efficient for HPV-related cancer prevention

University Student’s Start-Up Expands, Connecting Small Coffee Farmers to the World

FSU physicists will study nuclear reactions of stars with support from National Science Foundation

Warning: don’t miss Thanksgiving dinner, it’s more meaningful than you think

Roswell Park Launches First-of-Its-Kind Oncology Training Program for Nurse-Scientists With $2M NCI Grant

UT Southwestern brings first-of-its-kind radiation oncology to new $177M campus in Fort Worth Medical District

Tips and recipes for a healthy holiday season from a doctor and a dietitian

X-ray Measurements Reveal an Unexpected Role for Copper in Photocatalysts

26 Nov, 2024

Advance in the Treatment of Acute Heart Failure Identified

April 26, 2024 sarah JonasResearch Results

A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death.

Dapagliflozin reduces risk for hospitalization in patients with CKD with or without diabetes

December 5, 2022 sarah JonasResearch Results

Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced the risk for hospitalization for any cause in patients with chronic kidney disease (CKD) with and without type 2 diabetes.